The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Yutaka ShimazuJunya KandaYoshiyuki OndaShin-Ichi FuchidaKensuke OhtaYuji ShimuraSatoru KosugiRyosuke YamamuraMitsuhiro MatsudaHitoshi HanamotoYoko AdachiNaoyuki AnzaiMasaaki HottaKentaro FukushimaHideo YagiSatoshi YoshiharaYasuhiro TanakaTeruhito TakakuwaHirokazu TanakaHirohiko ShibayamaNobuhiko UoshimaNaoki HosenTomoki ItoChihiro ShimazakiItaru MatsumuraJunya KurodaAkifumi Takaori-KondoMasayuki HinoPublished in: Cancer immunology, immunotherapy : CII (2024)
We found that the patients with higher LMR (≥ 4) could obtain longer PFS and OS under the Isa-PD regimen. Other cohort studies of isatuximab treatment might be necessary to substantiate our results.